Benoist GE, et al. – In this assessment, the clinicians evaluated the prevalence of potential drug-drug interactions (DDIs) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide. They reported a high prevalence of potential DDIs. Between the three drug interaction compendia, the inclusion and grading of potential DDIs were highly variable. This problem requires a critical concern from physicians, nurses, and pharmacists, in order to implement intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.